Schizoaffective disorder is a psychiatric diagnosis describing a situation where both the symptoms of mood disorder and psychosis are present. The disorder usually begins in early adulthood, and is more common in women.
There are two sub-types of schizoaffective disorder: the bipolar type and the depressive type. The bipolar type has a better prognosis than the depressive type, which can have a residual defect with the passing of time. Bipolar schizoaffective disorder is more similar to bipolar disorder than schizophrenia. People with bipolar disorder may also suffer from isolated episodes of psychotic symptoms.
Social security staff are no medico's however they do have medical staff (psychiatrists) that review medical certificates, and liaise with the client, med carts may require to be re submitted every 3 months and if they (social security) accept it as permanent (2 years or longer) you will get Disability benefit. Otherwise you will get only the sickness benefit which is tempoary.
Maybe your medico needs to complete more details for them to understand your condition. They won't just accept what you say, it needs to be medically confirmed.
The psychiatric treatment for schizoaffective disorder is a combination of therapy and medicine. A licensed psychiatrist will prescribe different combinations of medicine to the patient in order to find the combination that works. Each person responds differently to medicine.
Common medicines prescribed to treat schizoaffective disorder:
Combining lithium, carbamazepine, or valproate with a neuroleptic has been shown to be superior to neuroleptics alone in schizoaffective patients with manic symptoms. The degree of benefit for an individual patient should be considered carefully, as each of these agents carries an additional set of risks. Lithium-neuroleptic combinations may produce severe extrapyramidal reactions or confusion in some patients. Carbamazepine or valproate are frequently employed when lithium is not effective or well tolerated. Granulocytopenia can occur during the first few weeks of carbamazepine treatment, and neuroleptic blood levels may be increased substantially due to hepatic enzyme induction. Valproate can cause liver toxicity and platelet dysfunction, although those problems are uncommon. More recently, the anticonvulsants lamotrigine and gabapentin have shown promise in the treatment of manic symptoms, although there have been no systematic studies of their use in schizoaffective disorder at this time. Calcium channel blockers such as verapamil may also be an effective treatment for manic symptoms but are seldom prescribed for that purpose. Benzodiazepines such as lorazepam and clonazepam are effective adjunctive treatment agents for acute manic symptoms, but long-term use may result in dependency.
Often a sleeping pill will initially be prescribed to allow the patient rest from his or her anxiety or hallucinations.
In addition to pharmaceutical medications, some who suffer from schizoaffective disorder have claimed to benefit from medicinal marijuana (cannabis). This claim, however, has not been substantiated by clinical trials and there is no available clinical literature on effective dosage levels.Additionally, psychiatrists report that with patients who are heavy cannabis users, it is often difficult to separate the symptoms of the disorder from those due to the cannabis.
People with schizoaffective disorder have a greater chance of returning to a previous level of functioning than patients with other psychotic disorders. However, long-term treatment may be necessary and individual outcomes will vary.
· 1 decade ago